AIMS: Because of the high prevalence of prostatic cancer and the limitations of its treatment, enormous effort has been put into the development of new therapeutic modalities. One potential tool is the use of cyclin dependent kinase (CDK) inhibitors, which are based on the trisubstituted derivatives of purine. The aim of this study was to analyse alterations of the regulatory pathways in both androgen sensitive and androgen insensitive prostatic cancer cell lines (LNCaP and DU-145, respectively) after blockage of the cell cycle by the synthetic CDK inhibitors, olomoucine and bohemine. METHODS: The effects of olomoucine and bohemine were studied on the following parameters: (1) cell proliferation, by measurement of DNA content; (2) viability, by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) and/or XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide) test; and (3) the expression of p53, pRB, Bcl-2, Bax, p16, p21, p27, cyclins A, B, D1, E, p34(cdc2), and the androgen receptor (AR), by western blot analysis. RESULTS: Both olomoucine and bohemine were potent inhibitors of growth and viability; however, bohemine was two to three times more effective than olomoucine. The sensitivity of LNCaP cells to both agents was significantly higher. After treatment, both cell lines revealed quite different spectra of protein expression. CONCLUSIONS: These results indicate the existence of specific cell cycle regulating pathways in both cell lines, which may be associated with both p53 and AR status. CDK inhibitors exhibited valuable secondary effects on the expression of numerous regulators and thus may modulate the responsiveness of tumour cells to treatment, including treatment with hormone antagonists.

Laboratory of Molecular Pathology Faculty of Medicine Centre of Molecular Biology and Medicine Palacký University Hnevotínská 3 CZ 77515 Olomouc Czech Republic

Zobrazit více v PubMed

Havlíček L, Hanuš J, Veselý J, et al. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 1997;40:408–12. PubMed

Garrett MD, Fattaey A. CDK inhibition and cancer therapy. Current Opin Genet Dev 1999;9:104–11. PubMed

Abraham RT, Acquarone M, Andersen A, et al. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol Cell 1995;83:105–20. PubMed

Meijer L, Bisagni E, Legraverend M, et al. Novel purine derivatives having, in particular, antiproliferative properties, and biological uses thereof. Organisation mondiale de la propriete intellectuelle. 1997;WO 97/20842.

Schuurmans ALG, Bolt J, Veldscholte J, et al. Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones. Steroid Biochem Mol Biol 1991;40:193–7. PubMed

Dorkin TJ, Neal DE. Basic science aspects of prostate cancer. Semin Cancer Biol 1997;8:21–7. PubMed

Apakama I, Robinson MC, Walter NM, et al. Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996;74:1258–62. PubMed PMC

Magi-Galluzzi C, Murphy M, Cangi G et al. Proliferation, apoptosis and cell cycle regulation in prostatic carcinogenesis. Quant Cytol Histol 1998;20:343–50. PubMed

Bai XZ, Masters JR, O’Donoghue N, et al. Prognostic markers in clinically localised prostate cancer. Int J Pathol 1999;14:785–91. PubMed

Klocker H, Culig Z, Hobish A, et al. Androgen receptor alterations in prostatic carcinoma. Prostate 1994;25:266–73. PubMed

Rao J, Otto WR. Fluorimetric DNA assay for cell growth estimation. Anal Biochem 1992;207:186–92. PubMed

Alley MC, Scudieco DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589–601. PubMed

Roehm NW, Rodgers GH, Hatfield SM, et al. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. Immunol Methods 1991;142:257–65. PubMed

Lee VH, Dunbar BS. Sample preparation for protein electrophoresis and transfer. In: Dunbar BS, ed. Protein blotting: a practical approach. Oxford: Oxford University Press, 1994:87–101.

Carroll AG, Voeller HJ, Surgars L, et al. p53 oncogene mutations in the three human prostate cancer cell lines. Prostate 1993;23:123–4. PubMed

Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967–9. PubMed

Beham AW, Sarkiss M, Brisbay S, et al. Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cell in vivo. Int J Mol Med 1998;1:953–9. PubMed

Fan S, Wang J-A, Yuan R, et al. BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 1998;16:3069–82. PubMed

Tilley WD, Wilson CM, Marcelli M, et al. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990;50:5382–6. PubMed

Dorai T, Perlman H, Walsh K, et al. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. Int J Cancer 1999;82:846–52. PubMed

Cheney IW, Neuteboom STC, Vaillancourt M-T, et al. Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes. Cancer Res 1999;59:2318–23. PubMed

Elgie AW, Sargent JM, Taylor CG, et al. An in vitro study of blast cell metabolism in acute myeloid leukaemia using MTT assay. Leuk Res 1996;20:407–13. PubMed

Marcelli M, Marani M, Li X, et al. Heterogeneous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to staurosporine-induced apoptosis, expression of Bcl-2 family members, and caspase activation. Prostate 2000;42:260–73. PubMed

Rokhlin OW, Gudkov AV, Kwek S, et al. p53 is involved in tumor necrosis factor-α-induced apoptosis in the human prostatic carcinoma cell line LNCaP. Oncogene 2000;19:1959–68. PubMed

Ng AY, Bales W, Veltri RW. Phenylbutyrate-induced apoptosis and differential expression of Bcl-2, Bax, p53 and Fas in human prostate cancer cell lines. Anal Quant Cytol Histol 2000;22:45–54. PubMed

Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997;243:527–36. PubMed

Hajdúch M, Nosková V, Feketová G, et al. Olomoucine derived synthetic cyclin dependent kinase inhibitors—new generation of potent anti-cancer drugs. In: Pieters R, Veerman A, Kaspers GJL, eds. Drug resistance in leukaemia and lymphoma, advances in experimental medicine and biology. New York: Kluwer Academic/Plenum Press, 1999:341–53. PubMed

Alberio R, Kubelka M, Zakhartchenko V, et al. Activation of bovine oocytes by specific inhibition of cyclin-dependent kinases. Mol Reprod Dev 2000;55:422–32. PubMed

Veselý J, Havlíček L, Strnad M, et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1994;224:771–86. PubMed

Schutte B, Nieland L, van Engeland M, et al. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp Cell Res 1998;236:4–15. PubMed

Hajdúch M, Kolář Z, Novotný R, et al. Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin dependent kinase inhibitor olomoucine. Anticancer Drugs 1997;8:1007–10. PubMed

Harnessing p53 for targeted cancer therapy: new advances and future directions